Thyroid Cancer News and Research

Latest Thyroid Cancer News and Research

Researchers find novel drug target for anaplastic thyroid carcinomas

Anaplastic thyroid carcinomas are aggressive tumors that do not respond to traditional radio- or chemotherapeutic agents, and there currently is no cure or effective treatment available. Median survival from diagnosis is 5 months, and although ATC accounts for only 1.7% of all thyroid cancers in the U.S., it is responsible for a large proportion of thyroid cancer-related deaths.

17 Oct 2013

Study shows treatment for hypothyroidism is not associated with weight loss in most people

Decreased thyroid function, or hypothyroidism, is commonly associated with weight gain. But contrary to popular belief, effective treatment with levothyroxine (LT4) to restore normal thyroid hormone levels is not associated with clinically significant weight loss in most people.

17 Oct 2013

Cdk5 protein may play crucial role in deadly form of thyroid cancer

A specific protein once thought to exist only in the brain may play a crucial role in a deadly form of thyroid cancer, as well as other cancers, and provide a fresh target for researchers seeking ways to stop its progression, UT Southwestern Medical Center researchers report today in Cancer Cell.

15 Oct 2013

Discoveries pave way for use of new therapies for advanced thyroid cancer

For many years, patients with advanced thyroid cancer faced bleak prospects and no viable treatment options. But now, building on recent discoveries about the genetics and cell signaling pathways of thyroid tumors, researchers are developing exciting new weapons against the disease, using kinase inhibitors that target tumor cell division and blood vessels.

30 Sep 2013

Comprehensive guide for translational, basic research scientists fills gap in thyroid research field

Despite tens of thousands of studies in the literature on the thyroid gland, thyroid hormone, and thyroid disease, lack of standardization in study design makes it difficult to compare the results and apply them to the development of improved diagnostic and treatment approaches.

6 Sep 2013

Ohio State University researchers awarded NCI grant to further study thyroid cancer

The National Cancer Institute has awarded a five-year, $11.3 million grant to a team of researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute to further their studies on thyroid cancer.

5 Sep 2013

Low-risk thyroid cancers are overdiagnosed and overtreated

An increasing gap between the incidence of thyroid cancer and deaths from the disease suggests that low-risk cancers are being overdiagnosed and overtreated, a study from the Mayo Clinic Center for the Science of Health Care Delivery finds. The study appears in the current issue of the British Medical Journal.

28 Aug 2013

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted Priority Review designation to the supplemental New Drug Application for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

27 Aug 2013

Thyroid ultrasound imaging may identify patients with low risk of cancer, can help postpone biopsy

Thyroid ultrasound imaging could be used to identify patients who have a low risk of cancer for whom biopsy could be postponed, according to a study by Rebecca Smith-Bindman, M.D., of the University of California, San Francisco, and colleagues.

27 Aug 2013

Added benefit of thyroid cancer drug vandetanib not proven

Vandetanib (trade name: Caprelsa) has been approved in Germany since February 2012 for the treatment of adult patients who have a particular form of aggressive thyroid cancer. In a new benefit assessment, the German Institute for Quality and Efficiency in Health Care has now examined the added benefit of the drug pursuant to the Act on the Reform of the Market for Medicinal Products.

3 Aug 2013

Array BioPharma announces positive results from ARRY-502 Phase 2 trial for allergic asthma

Array BioPharma Inc. today announced positive results from a placebo-controlled, randomized, double‑blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist.

23 Jul 2013

Jersey Shore to present free educational conference focusing on thyroid cancer patients, survivors

On Friday, August 2, 2013, Jersey Shore, in partnership with Meridian Cancer Care and the Light of Life Foundation, will present a free educational conference featuring Meridian Health specialists.

22 Jul 2013

Array BioPharma achieves milestone for initiation of MEK162 Phase 3 trial in patients with LGSOC

Array BioPharma Inc. announced today that a $5 million milestone was achieved after the start of Array's Phase 3 clinical trial in patients with low-grade serous ovarian cancer.

2 Jul 2013

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

1 Jul 2013

Mount Sinai researchers present several new studies at ENDO 2013

Researchers from the Icahn School of Medicine at Mount Sinai will present several new studies at ENDO 2013, The Endocrine Society's Annual Meeting & Expo from June 15-18 in San Francisco.

17 Jun 2013

Dr. Todd Darmody honored with 2012 Compassionate Doctor Certification

Patients' Choice has announced that Dr. Todd Darmody, MD was one of a select few physicians honored with the prestigious 2012 Compassionate Doctor Certification.

15 Jun 2013

American Academy of Otolaryngology publishes new guideline on “Improving Voice Outcomes after Thyroid Surgery”

The American Academy of Otolaryngology-Head and Neck Surgery Foundation on Tuesday published a new Clinical Practice Guideline on "Improving Voice Outcomes after Thyroid Surgery" to recognize the importance of the patient's voice and the potential impact thyroid surgery can have on it.

4 Jun 2013

Study: Mutations in gene NTRK1 cause a subset of lung cancers

To the list of oncogenic drivers of lung cancer that includes ALK, EGFR, ROS1 and RET, results of a University of Colorado Cancer Center study presented at ASCO 2013 show that mutations in the gene NTRK1 cause a subset of lung cancers.

4 Jun 2013

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced clinical data demonstrating the utility of VB-111's in targeted cancer treatment.

3 Jun 2013

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology's annual meeting.

3 Jun 2013

Thyroid Cancer News and Research

Latest Thyroid Cancer News and Research

Researchers find novel drug target for anaplastic thyroid carcinomas

Study shows treatment for hypothyroidism is not associated with weight loss in most people

Cdk5 protein may play crucial role in deadly form of thyroid cancer

Discoveries pave way for use of new therapies for advanced thyroid cancer

Comprehensive guide for translational, basic research scientists fills gap in thyroid research field

Ohio State University researchers awarded NCI grant to further study thyroid cancer

Low-risk thyroid cancers are overdiagnosed and overtreated

FDA grants Priority Review designation to sNDA for Nexavar tablets

Thyroid ultrasound imaging may identify patients with low risk of cancer, can help postpone biopsy

Added benefit of thyroid cancer drug vandetanib not proven

Array BioPharma announces positive results from ARRY-502 Phase 2 trial for allergic asthma

Jersey Shore to present free educational conference focusing on thyroid cancer patients, survivors

Array BioPharma achieves milestone for initiation of MEK162 Phase 3 trial in patients with LGSOC

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Mount Sinai researchers present several new studies at ENDO 2013

Dr. Todd Darmody honored with 2012 Compassionate Doctor Certification

American Academy of Otolaryngology publishes new guideline on “Improving Voice Outcomes after Thyroid Surgery”

Study: Mutations in gene NTRK1 cause a subset of lung cancers

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Thyroid Cancer News and Research

Latest Thyroid Cancer News and Research

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Newsletters you may be interested in